Univariate analysis comparing patients with and without major protease inhibitor (PI) drug resistance mutations.

<p>Data collected from 65¹, 61², 60³, 59⁴, 28⁵, 43⁶, 40⁷, 42⁸ and 64⁹ patients respectively</p><p><b>Abbreviations:</b> ART = antiretroviral therapy; PI = protease inhibitors; IQR = interquartile range; BMI = body mass index; CD4 = CD4+ T-cell count in cells/mm³; CD4% = CD4 percentage; VL = HIV viral load; LDL = lower than detectable level; Nr = number; TB = tuberculosis; Ref = reference value; RTV-sPI = ritonavir as full-dose single protease inhibitor; ddLPV/r = double-dose boosted lopinavir; LPV/R⁺ = super-boosted lopinavir; NRTI = nucleoside reverse transcriptase inhibitor; TAMs = thymidine analogue mutations; NNRTI = non-nucleoside reverse transcriptase inhibitor</p><p>*From first failure time point (using LDL cut-off & >6 months on ART) to date of genotype</p><p>**Age- and sex-adjusted anthropometry according to WHO growth standards [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0133452#pone.0133452.ref022" target="_blank">22</a>]</p><p>#Corresponding p-value for VL<1000 = 0.036</p><p>Univariate analysis comparing patients with and without major protease inhibitor (PI) drug resistance mutations.</p

Comparison of projected susceptibility to antiretroviral medication in children with and without major protease inhibitor (PI) drug resistance mutations.

<p>Data collected from 65¹ and 64² patients respectively</p><p>Predicted drug susceptibility categories were determined through the Stanford HIVdb Algorithm</p><p><b>Abbreviations:</b> PI = protease inhibitors; LPV/r = ritonavir-boosted lopinavir; DRV/r = ritonavir-boosted darunavir; TPV/r = ritonavir-boosted tipranavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; EFV = efavirenz; ETR = etravirine; NRTI = nucleoside reverse transcriptase inhibitor; ABC = abacavir; AZT = zidovudine; d4T = stavudine; TDF = tenofovir; 3TC = lamivudine</p><p>Comparison of projected susceptibility to antiretroviral medication in children with and without major protease inhibitor (PI) drug resistance mutations.</p

Clinical and laboratory findings of the cohort.

<p>Data collected from 65¹, 61², 60³, 59⁴ and 47⁵ patients respectively</p><p><b>Abbreviations:</b> ART = antiretroviral therapy; PI = protease inhibitor; IQR = interquartile range; BMI = Body mass index; CD4 = CD4+ T-cell count in cells/mm³; CD4% = CD4 percentage; VL = HIV viral load in log₁₀ copies/ml; Nr = number; WHO stage = HIV disease staging according to World Health Organization; d4T = stavudine; 3TC = lamivudine; LPV/r = boosted lopinavir; RTV-sPI = ritonavir as full-dose single protease inhibitor; LPV/R⁺ = super-boosted lopinavir; ABC = abacavir; AZT = zidovudine; TB = tuberculosis.</p><p>*From first failure time point (using LDL cut-off & >6 months on ART) to date of genotype</p><p>**Age- and sex-adjusted anthropometry according to WHO growth standards [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0133452#pone.0133452.ref022" target="_blank">22</a>]</p><p>Clinical and laboratory findings of the cohort.</p

Kaplan-Meier curve of time to virological suppression among children with or without use of ritonavir as single protease inhibitor (RTV-sPI) at the time of protease inhibitor (PI) initiation.

<p>Groups: (A) No RTV-sPI exposure or history of exposure to TB therapy; (B) No RTV-sPI exposure, on TB treatment at time of PI initiation; (C) History of RTV-sPI exposure, and on TB treatment at time of PI initiation.</p